Xeris Pharmaceuticals Stock Today
| XERS Stock | USD 3.61 0.15 4.34% |
Performance10 of 100
| Odds Of DistressOver 64
|
Xeris Pharmaceuticals is selling for under 3.61 as of the 5th of January 2025; that is 4.34 percent increase since the beginning of the trading day. The stock's lowest day price was 3.47. Xeris Pharmaceuticals has more than 64 % chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. The performance scores are derived for the period starting the 6th of December 2024 and ending today, the 5th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of June 2018 | Category Healthcare | Classification Health Care |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. The company has 149.08 M outstanding shares of which 9.52 M shares are at this time shorted by private and institutional investors with about 5.53 trading days to cover. More on Xeris Pharmaceuticals
Moving against Xeris Stock
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.52 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.52 | UPC | Universe Pharmaceuticals | PairCorr |
| 0.5 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.47 | DNLI | Denali Therapeutics | PairCorr |
| 0.45 | LLY | Eli Lilly | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Xeris Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Paul Edick | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsXeris Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Xeris Pharmaceuticals' financial leverage. It provides some insight into what part of Xeris Pharmaceuticals' total assets is financed by creditors.
| |||||
Xeris Pharmaceuticals (XERS) is traded on NASDAQ Exchange in USA. It is located in 180 North LaSalle Street, Chicago, IL, United States, 60601 and employs 377 people. Xeris Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 538.18 M. Xeris Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 149.08 M outstanding shares of which 9.52 M shares are at this time shorted by private and institutional investors with about 5.53 trading days to cover.
Xeris Pharmaceuticals currently holds about 111.55 M in cash with (47.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.82.
Check Xeris Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationXeris Pharmaceuticals retains a total of 149.08 Million outstanding shares. 30% of Xeris Pharmaceuticals outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Xeris Ownership Details
Xeris Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2024-09-30 | 1.4 M | |
| Northern Trust Corp | 2024-09-30 | 1.2 M | |
| Walleye Trading Advisors, Llc | 2024-09-30 | 1.1 M | |
| Aqr Capital Management Llc | 2024-09-30 | 1.1 M | |
| Redmile Group, Llc | 2024-09-30 | 1 M | |
| Bank Of America Corp | 2024-09-30 | 1 M | |
| D. E. Shaw & Co Lp | 2024-09-30 | 985 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 836.4 K | |
| Kennedy Capital Management Inc | 2024-09-30 | 604.9 K | |
| Blackrock Inc | 2024-09-30 | 10.7 M | |
| Vanguard Group Inc | 2024-09-30 | 7.8 M |
Xeris Pharmaceuticals Historical Income Statement
Xeris Stock Against Markets
Xeris Pharmaceuticals Corporate Management
| PharmD D | Senior Affairs | Profile | |
| Beth JD | Chief Secretary | Profile | |
| Steven Pieper | Chief Officer | Profile | |
| Dr MBA | CoFounder Officer | Profile | |
| Paul JD | Senior Advisor | Profile |
Already Invested in Xeris Pharmaceuticals?
The danger of trading Xeris Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xeris Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xeris Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xeris Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.